Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;51(2):162-72.
doi: 10.1007/s00535-015-1104-x. Epub 2015 Jul 21.

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

Tadashi Namisaki  1 , Ryuichi Noguchi  2 , Kei Moriya  2 , Mitsuteru Kitade  2 , Yosuke Aihara  2 , Akitoshi Douhara  2 , Norihisa Nishimura  2 , Kosuke Takeda  2 , Yasushi Okura  2 , Hideto Kawaratani  2 , Hiroaki Takaya  2 , Kenichiro Seki  2 , Hitoshi Yoshiji  2
Affiliations

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

Tadashi Namisaki et al. J Gastroenterol. 2016 Feb.

Abstract

Background and aims: Ursodeoxycholic acid (UDCA) is considered to be effective in the treatment of nonalcoholic steatohepatitis (NASH), particularly in combination with other pharmacological agents. UDCA reportedly counteracts the effects of endotoxemia. Previously, we demonstrated attenuated hepatic fibrogenesis and suppression of activated hepatic stellate cells (Ac-HSC) with an angiotensin-II (AT-II) type 1 receptor blocker (ARB). Here we evaluated the simultaneous effect of both agents on hepatic fibrogenesis in a rat model of NASH.

Methods: Fischer 344 rats were fed a choline-deficient L-amino-acid-defined (CDAA) diet for 8 weeks. The therapeutic effect of UDCA and ARB was evaluated along with hepatic fibrogenesis, lipopolysaccharide (LPS)-Toll-like receptor 4 (TLR4) regulatory cascade, and intestinal barrier function. The direct inhibitory effect of both UDCA and ARB on Ac-HSC was assessed in vitro.

Results: Both UDCA and ARB had a potent inhibitory effect on hepatic fibrogenesis with suppression of the HSC activation and hepatic expression of transforming growth factor (TGF)-β1 and TLR4. UDCA decreased intestinal permeability by ameliorating zonula occuludens-1 (ZO-1) disruption induced by the CDAA diet. ARB was found to directly suppress regulation of Ac-HSC.

Conclusions: UDCA and ARB have a synergistic repressive effect on hepatic fibrogenesis by counteracting endotoxemia induced by intestinal barrier dysfunction and suppressing the activation of Ac-HSC. Because both agents are currently used in clinical practice, combined UDCA and ARB may represent a promising novel therapeutic approach for NASH.

Keywords: ARB; Hepatic fibrogenesis; Nonalcoholic steatohepatitis; UDCA.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hepatology. 1998 Apr;27(4):1003-12 - PubMed
    1. Nat Med. 2007 Nov;13(11):1324-32 - PubMed
    1. Hepatol Res. 2013 Jul;43(7):765-74 - PubMed
    1. Hepatol Res. 2011 Jul;41(7):647-59 - PubMed
    1. J Nutr. 2011 May;141(5):769-76 - PubMed

MeSH terms

LinkOut - more resources

  NODES
INTERN 4
twitter 2